Bernard Cosyns

Bernard Cosyns

Auto-generated profile, based on publicly available information

Bernard Cosyns

Cardiology Department, Centrum voor hart en vaatziekten, Universitair Ziekenhuis Brussel, Free University of Brussels , Brussels 1090

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
Fabien PrazFabien Praz
Fabien Praz
MBMichael Borger
Michael Borger
JLJonas Lanz
Jonas Lanz
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
AAAna Abreu
Ana Abreu
NMNarain Moorjani
Narain Moorjani

16 March 2022 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PLPatrizio Lancellotti
Patrizio Lancellotti
PPPhilippe Pibarot
Philippe Pibarot
JCJohn Chambers
John Chambers
GCGiovanni La Canna
Giovanni La Canna
MPMauro Pepi
Mauro Pepi
TIthe Scientific Document Committee of the European Association of Cardiovascular Imaging
the Scientific Document Committee of the European Association of Cardiovascular Imaging
Valvular regurgitation represents an important cause of cardiovascular morbidity and mortality. Imaging is pivotal in the evaluation of native valve regurgitation and echocardiography is the primary imaging modality for this purpose. The imaging assessment of valvular regurgitation should integrate quantification of the regurgitation, assessment of the valve anatomy and function, and the consequences of valvular disease on cardiac chambers. In clinical practice, the management of patients with valvular regurgitation largely relies on the results of imaging. It is crucial to provide standards that aim at establishing a baseline list of measurements to be performed when assessing native valve regurgitation. The present document aims to present clinical guidance for the multi-modality imaging assessment of native valvular regurgitation.

18 June 2020 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
MDMarc R Dweck
Marc R Dweck
ABAnda Bularga
Anda Bularga
RHRebecca T Hahn
Rebecca T Hahn
RBRong Bing
Rong Bing
KLKuan Ken Lee
Kuan Ken Lee
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Aims: To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. Methods and results: In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52–71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75–5.05) and cardiac troponin (OR 1.69, 95% CI 1.13–2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73–6.10) for the latter. Echocardiography changed management in 33% of patients. Conclusion: In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.

11 August 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
ASAvi Sabbag
Avi Sabbag
BEBenjamin Essayagh
Benjamin Essayagh
JBJuan David Ramírez Barrera
Juan David Ramírez Barrera
CBCristina Basso
Cristina Basso
ABAna Berni
Ana Berni
PLPatrizio Lancellotti
Patrizio Lancellotti
Risk stratification scheme. Risk stratification aiming at assessing the risk of VAs and SCD in patients with MVP, involving two phases based on the clinical and imaging context and the uncovered arrhythmia. In the absence of ventricular tachycardia, phenotypic risk features will trigger the intensity of screening for arrhythmia. Green boxes indicate green heart consensus statements and yellow boxes indicate yellow heart consensus statements. High risk - sustained VT, polymorphic NSVT, fast (>180 bpm) NSVT, VT/NSVT resulting in syncope. ICD = implantable cardioverter defibrillator; LA = left atrium; LGE = late gadolinium enhancement; LV-EF = left ventricular ejection fraction; MAD = mitral annular disjunction; MV = mitral valve; PVCs = premature ventricular contractions; TWI = T-wave inversion; VT = ventricular tachycardia. #Additional ECG monitoring method may be used such as loop recorders.

3 April 2020 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
HSHelge Skulstad
Helge Skulstad
BCBernard Cosyns
Bernard Cosyns
Bogdan PopescuBogdan Popescu
Bogdan Popescu
MGMaurizio Galderisi
Maurizio Galderisi
GSGiovanni Di Salvo
Giovanni Di Salvo
TEThor Edvardsen
Thor Edvardsen
The coronavirus disease 2019 (COVID-19) pandemic has created new and unpredictable challenges for modern medicine and healthcare systems. Preliminary reports have demonstrated that older age, previous cardiovascular disease, diabetes, and hypertension are risk factors for increased mortality.1 Data on the cardiac affinity of the virus and its potential to harm the cardiovascular system and the mechanisms by which this occurs are sparse.2,3A systemic infection generally increases demand on the heart, and can exacerbate underlying cardiac conditions. When the lungs are heavily involved, as seen in COVID-19 patients, this may have a major impact on cardiac function, particularly that of the right ventricle. Finally, COVID-19 may have direct effects on the heart, as may some drugs being used in its treatment.

23 September 2014 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
BCBernard Cosyns
Bernard Cosyns
SPSven Plein
Sven Plein
PNPetros Nihoyanopoulos
Petros Nihoyanopoulos
OSOtto Smiseth
Otto Smiseth
SAStephan Achenbach
Stephan Achenbach
ODOn behalf of the European Association of Cardiovascular Imaging (EACVI) and European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases
On behalf of the European Association of Cardiovascular Imaging (EACVI) and European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases
Although pericardial diseases are common in the daily clinical practice and can result in a significant morbidity and mortality, imaging of patients with suspected or known pericardial disorders remain challenging. Multimodality imaging is part of the management of pericardial diseases. Echocardiography, cardiac computed tomography, and cardiovascular magnetic resonance are often used as complementary imaging modalities. The choice of one or multiple imaging modalities is driven by the clinical context or conditions of the patient. The scope of the present document is to highlight the respective role of each technique according to the clinical context in the diagnosis and management of pericardial diseases.